Search Results

evobrutinib 2 mg  | 98.04%

TargetMol

Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B -lymphocytes and macrophages. PreClinical research suggests it may be therapeutically useful in certain autoimmune diseases.

More Information Supplier Page

evobrutinib 1 mg  | 98.04%

TargetMol

Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B -lymphocytes and macrophages. PreClinical research suggests it may be therapeutically useful in certain autoimmune diseases.

More Information Supplier Page

Nampt-IN-1 25 mg  | 99.40%

TargetMol

Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.

More Information Supplier Page

Nampt-IN-1 10 mg  | 99.40%

TargetMol

Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.

More Information Supplier Page

Nampt-IN-1 5 mg  | 99.40%

TargetMol

Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.

More Information Supplier Page

Nampt-IN-1 2 mg  | 99.40%

TargetMol

Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.

More Information Supplier Page

Nampt-IN-1 1 mg  | 99.40%

TargetMol

Nampt-IN-1 (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.

More Information Supplier Page

evobrutinib 5 mg  | 98.04%

TargetMol

Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B -lymphocytes and macrophages. PreClinical research suggests it may be therapeutically useful in certain autoimmune diseases.

More Information Supplier Page

evobrutinib 10 mg  | 98.04%

TargetMol

Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B -lymphocytes and macrophages. PreClinical research suggests it may be therapeutically useful in certain autoimmune diseases.

More Information Supplier Page

evobrutinib 25 mg  | 98.04%

TargetMol

Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B -lymphocytes and macrophages. PreClinical research suggests it may be therapeutically useful in certain autoimmune diseases.

More Information Supplier Page